ANVS | Annovis Bio, Inc. Stock Overview

(Stock Exchange: NYSE)

Day's Range	6.45 - 6.84
52 Week Range	4.53 - 22.49
Beta	1.38
Implied Volatility	101.79%
IV Rank	14.65%
Day's Volume	158,013
Average Volume	235,209
Shares Outstanding	13,797,200
Market Cap	90,233,688
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-01-29

Valuation
Profitability
Growth
Health
P/E Ratio	-1.55
Forward P/E Ratio	N/A
EPS	-4.22
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6
Country	USA
Website	ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

ANVS's peers: ANIX, SAVA, AXSM, RVPH, MCRB, AVXL, IOVA, NVAX, TFFP, IMNM, INAB, ABOS, INZY, TERN, DAWN, GRTX, CUE, LTRN, GRCL, ATNM, SLS, SNPX, VERU

*Chart delayed

Analyzing fundamentals for ANVS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ANVS Fundamentals page.

Watching at ANVS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ANVS Technicals page.